Fueling growth by enabling IVD test development and manufacturing, deepening scientific capabilities and expanding cancer diagnostics scope to 8 of the 10 top cancers in the U.S. Investor conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman, chief executive officer and incoming executive chairman, and Marc Stapley , incoming chief executive officer, are
Study findings to be presented June 4 at ASCO Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2021-- Veracyte, Inc ., (Nasdaq: VCYT) announced today new data that show the company’s Afirma Xpression Atlas (XA) can identify clinically relevant gene fusions in thyroid nodule
- VANDAAM study findings confirm test predicts aggressive prostate cancer in African American men - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 25, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data from two studies that further demonstrate the Decipher ® Prostate Genomic
Company to hold webcast to discuss findings on Thursday, May 20 , at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced pivotal clinical validation data showing that the company’s noninvasive nasal swab test can significantly
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 18, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman, chief executive officer and incoming executive chairman, and Marc Stapley , incoming chief executive officer, are
New findings presented at ATS 2021 Conference also suggest novel test can be successfully enabled on nCounter Analysis System to support international expansion SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced that data reinforcing the
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta ® Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used
Bonnie Anderson , Cofounder and CEO, to Assume Active Role as Executive Chairman; Marc Stapley to Become Chief Executive Officer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 10, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced its executive
Total Revenue of $36.7 Million Increased 18%; Volume Grew 11% to 14,437 Tests Completed Acquisition of Decipher Biosciences, Expanding Reach Into 7 of the Top 10 Cancers in the United States Pivotal Validation Data for Percepta Nasal Swab Lung Cancer Test To Be Presented at ASCO Conference Call and
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
